Brief: Sirnaomics Says Loss For The Year $97.4 Mln
28/03/2023 10:05
March 28 (Reuters) - Sirnaomics Ltd 2257.HK :
* LOSS FOR THE YEAR US$97.4 MILLION VERSUS LOSS US$215.9
MILLION
* WELL POSITIONED TO DEVELOP NOVEL RNAI THERAPEUTICS FOR
CANCER,
FIBROSIS DISEASES, VIRAL INFECTION, AMONG OTHERS
* UNIT RNAIMMUNE EXPECTED TO ADVANCE TO AN IND APPLICATION
FOR
RIM730 WITH FDA IN Q1 OF 2023
* EXPECTS TO FURTHER ADVANCE STP705 SKIN CANCER FRANCHISE TO
LATE-STAGE DEVELOPMENT IN 2H23
* IMPACT OF COVID-19 ON OUR BUSINESS WILL REMAIN
Further company coverage: 2257.HK
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million